New Study Compares Low-Dose Atropine Eye Drops to Placebo for Myopia Control

JAMA Network

About The Study: In this randomized clinical trial of school-age children in the U.S. with low to moderate myopia (nearsightedness), atropine, 0.01%, eye drops administered nightly when compared with placebo did not slow myopia progression or axial elongation. These results do not support use of atropine, 0.01%, eye drops to slow myopia progression or axial elongation in U.S. children.

Authors: Michael X. Repka, M.D., M.B.A., of the Wilmer Eye Institute in Baltimore, is the corresponding author.

To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/

(doi:10.1001/jamaophthalmol.2023.2855)

/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.